Table 20Dose response reduction in migraine attacks by ≥50% from baseline with topiramate in adults

Reference
Risk of Bias
Topiramate Daily DosesEvents/Randomized With Larger vs. Smaller DoseRelative Risk (95% CI)Absolute Risk Difference (95% CI)Number Needed To Treat (95% CI)Attributable Events (95% CI)
Brandes, 2004229
Risk of bias Low
100mg vs. 50mg/day60/122
47/120
1.3 (0.9 to 1.7)0.10 (−0.02 to 0.23)NSNS
Silberstein, 200397
Risk of bias: Medium
100mg vs. 50mg/day68/125
41/117
1.5 (1.1 to 2.1)0.19 (0.07 to 0.31)5 (3 to 15)189 (67 to 312)
Silberstein, 2004230
Risk of bias: Low
100mg vs. 50mg/day69/128
45/125
1.5 (1.1 to 2.0)0.18 (0.06 to 0.30)6 (3 to 17)179 (58 to 300)
Pooled100mg vs. 50mg/day196/375
133/362
1.4 (1.2 to 1.7)0.16 (0.09 to 0.23)6 (4 to 12)157 (86 to 228)
Brandes, 2004229
Risk of bias: Low
100mg vs. 50mg/day57/121
47/120
1.2 (0.9 to 1.6)0.08 (−0.05 to 0.20)NSNS
Silberstein, 200397
Risk of bias: Medium
200mg/day vs. 50mg/day58/112
41/117
1.5 (1.1 to 2.0)0.17 (0.04 to 0.29)6 (3 to 24)167 (41 to 294)
Silberstein, 2004230
Risk of bias: Low
200mg/day vs. 50mg/day61/117
45/125
1.4 (1.1 to 1.9)0.16 (0.04 to 0.29)6 (4 to 26)161 (38 to 285)
Pooled200mg/day vs. 50mg/day176/350
133/362
1.4 (1.2 to 1.6)0.14 (0.06 to 0.21)7 (5 to 16)136 (64 to 208)
Brandes, 2004229
Risk of bias: Low
200mg/day vs. 100mg/day57/121
60/122
1.0 (0.7 to 1.2)−0.02 (−0.15 to 0.11)NSNS
Silberstein, 200397
Risk of bias: Medium
200mg/day vs. 100mg/day58/112
68/125
1.0 (0.8 to 1.2)−0.02 (−0.15 to 0.11)NSNS
Silberstein, 2004230
Risk of bias: Low
200mg/day vs. 100mg/day61/117
69/128
1.0 (0.8 to 1.2)−0.02 (−0.14 to 0.11)NSNS
Pooled200mg/day vs. 100mg/day176/350
196/375
1.0 (0.8 to 1.1)−0.02 (−0.09 to 0.05)NSNS

CI = confidence interval; NS = not significant

Bold = significant at 95% confidence limit when 95% CI of attributable events per 1,000 treated do not include 0.

Number needed to treat and number of attributable events were calculated for statistically significant differences.

From: Results

Cover of Migraine in Adults: Preventive Pharmacologic Treatments
Migraine in Adults: Preventive Pharmacologic Treatments [Internet].
Comparative Effectiveness Reviews, No. 103.
Shamliyan TA, Kane RL, Taylor FR.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.